KPTI (Karyopharm Therapeutics) Total Receivables: $23.4 Mil (As of Mar. 2026)


KPTI Karyopharm Therapeutics Inc KPTI
52 GF Score
Price $9.60
GF Value $6.34
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Karyopharm Therapeutics Total Receivables?

Karyopharm Therapeutics KPTI +0.63% 52 Total Receivables is $23.4 Mil as of Mar. 2026. GuruFocus rates KPTI with a GF Score™ of 52/100 and a GF Value™ of $6.34 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Karyopharm Therapeutics's Total Receivables for the quarter that ended in Mar. 2026 was $23.4 Mil.

Karyopharm Therapeutics Total Receivables Related Terms

Karyopharm Therapeutics Total Receivables Historical Data

* Premium members only.

The historical data trend for Karyopharm Therapeutics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karyopharm Therapeutics Total Receivables Chart

Karyopharm Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.50 47.09 26.96 30.77 26.18

Karyopharm Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.24 32.93 31.88 26.18 23.36
KPTI
52GF Score
Karyopharm Therapeutics Inc KPTI
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Karyopharm Therapeutics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $23.4 Mil mean?
Karyopharm Therapeutics (KPTI) has a Total Receivables of $23.4 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Karyopharm Therapeutics and its competitors.
Is Karyopharm Therapeutics' Total Receivables too high?
Karyopharm Therapeutics' current Total Receivables is $23.4 Mil. Overall, Karyopharm Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' Total Receivables compare to CHRS and TARA?
Karyopharm Therapeutics' Total Receivables of $23.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Karyopharm Therapeutics and its competitors. Karyopharm Therapeutics's current Total Receivables is $23.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (KPTI) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.34, compared to a current price of $9.60 — trading 51.4% above its estimated fair value. The current Total Receivables is $23.4 Mil. Karyopharm Therapeutics' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Karyopharm Therapeutics (KPTI), the current Total Receivables is $23.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?

Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued. The current stock price of $9.60 is trading 51.4% above its estimated GF Value™ of $6.34. GuruFocus considers Karyopharm Therapeutics to be Significantly Overvalued.

Key valuation signals for KPTI:

  • Total Receivables: $23.4 Mil
  • GF Value™: $6.34 vs. price of $9.60 (51.4% above fair value)
  • GF Score™: 52/100 with 8 warning signs

No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Karyopharm Therapeutics Business Description

Other Exchanges 25K0:Germany
Address 85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
52GF Score

Get the complete analysis for KPTI

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.60
Price
$6.34
GF Value